Refine
Has Fulltext
- no (2)
Document Type
- Article (2)
Language
- English (2)
Is part of the Bibliography
- yes (2)
Keywords
- Fusion (1)
- Gap junction (1)
- Glioma (1)
- Mesenchymal stem cell (1)
- Syncytium (1)
Institute
Malignant gliomas are a fatal disease lacking sufficient possibilities for early diagnosis and chemical markers to detect remission or relapse. The recruitment of progenitor cells such as mesenchymal stem cells (MSC) is a main feature of gliomas. Stromal cell-derived factor-1 (SDF-1), a chemokine produced in glioma cell lines, enhances migration in MSC and has been associated with cell survival and apoptosis in gliomas. Therefore, this study was performed to evaluate (i) whether SDF-1 and its receptors are expressed in human malignant gliomas in situ and (ii) if SDF-1 might potentially play a role in recruiting MSCs into human glioma. In glioblastoma tissue, immunohistochemistry revealed that SDF-1 and its receptor CXCR4 are expressed in regions of angiogenesis and necrosis, and qPCR showed that SDF-1 is elevated. Public expression data indicated that CXCR4 was upregulated. The latter data also illustrate that SDF-1 could be up- or downregulated in glioma compared to normal brain in a transcript-specific manner. In plasma, SDF-1 is elevated in glioma patients. The level is reduced by both dexamethasone intake and surgery. Dexamethasone also decreased SDF-1 production in cells in vitro. The undirected migration of human MSC (hMSC) was not enhanced by the addition of SDF-1. However, SDF-1 stimulated directed invasion of hMSC in a dose-dependent manner. Taken together, we show that SDF-1 is a potent chemoattractant of progenitor cells such as hMSCs and that its expression is elevated in glioma tissue, which results in elevated SDF-1 levels in the patient's plasma samples with concomittant decrease after tumor resection. The fact that elevated SDF-1 plasma levels are significantly decreased after tumor surgery could be a first hint that SDF-1 might act as tumor marker for malignant gliomas in order to detect disease progression or remission, respectively.
Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro
(2012)
The interaction of human mesenchymal stem cells (hMSCs) and tumor cells has been investigated in various contexts. HMSCs are considered as cellular treatment vectors based on their capacity to migrate towards a malignant lesion. However, concerns about unpredictable behavior of transplanted hMSCs are accumulating. In malignant gliomas, the recruitment mechanism is driven by glioma-secreted factors which lead to accumulation of both, tissue specific stem cells as well as bone marrow derived hMSCs within the tumor. The aim of the present work was to study specific cellular interactions between hMSCs and glioma cells in vitro. We show, that glioma cells as well as hMSCs differentially express connexins. and that they interact via gap-junctional coupling. Besides this so-called functional syncytium formation, we also provide evidence of cell fusion events (structural syncytium). These complex cellular interactions led to an enhanced migration and altered proliferation of both, tumor and mesenchymal stem cell types in vitro. The presented work shows that glioma cells display signs of functional as well as structural syncytium formation with hMSCs in vitro. The described cellular phenomena provide new insight into the complexity of interaction patterns between tumor cells and host cells. Based on these findings, further studies are warranted to define the impact of a functional or structural syncytium formation on malignant tumors and cell based therapies in vivo.